Related Experiment Video
Updated: Feb 2, 2026

Profiling Sensitivity to Targeted Therapies in EGFR-Mutant NSCLC Patient-Derived Organoids
Published on: November 22, 2021
MET amplification increases the metastatic spread of EGFR-mutated NSCLC
Simon Baldacci1, Zoulika Kherrouche2, Vincent Cockenpot3
1Thoracic Oncology Department, CHU Lille, Siric OncoLille, F-59000, Lille, France; Univ Lille, Lille, France; Univ. Lille, CNRS, Institut Pasteur de Lille, UMR 8161 - M3T - Mechanisms of Tumorigenesis and Targeted Therapies, F-59000, Lille, France.
Background:
Five to 20% of metastatic EGFR-mutated non-small cell lung cancers (NSCLC) develop acquired resistance to EGFR tyrosine kinase inhibitors (EGFR-TKI) through MET amplification. The effects of MET amplification on tumor and patient phenotype remain unknown.
Methods:
We investigated,in vitro and in vivo, the impact of MET amplification on the biological properties of the HCC827 cell line, derived from an EGFR-mutated NSCLC. We further evaluated the time to new metastases after EGFR-TKI progression in EGFR-mutated NSCLC, exhibiting MET amplification or high MET overexpression.
Results:
MET amplification significantly enhanced proliferation, anchorage independent growth, anoikis resistance, migration, and induced an epithelial to mesenchymal transition. In vivo, MET amplification significantly increased the tumor growth and metastatic spread. Treatment with a MET-TKI reversed this aggressive phenotype. We found that EGFR-mutated NSCLC patients exhibiting MET amplification on a re-biopsy, performed after EGFR-TKI progression, displayed a shorter time to new metastases after EGFR-TKI progression than patients with high MET overexpression but no MET amplification.
Conclusion:
MET amplification increases metastatic spread even in the context of an already pre-existing strong driver mutation such as EGFR mutation. These results prompt development of therapeutic strategies aiming at preventing emergence of MET amplification.
Insights
MET amplification in EGFR-mutated non-small cell lung cancer (NSCLC) drives aggressive tumor growth and metastasis. Targeting MET can reverse this phenotype, suggesting new therapeutic strategies for resistant lung cancer.
Area of Science:
- Oncology
- Molecular Biology
- Cancer Genetics
Background:
- Acquired resistance to EGFR tyrosine kinase inhibitors (EGFR-TKI) in metastatic EGFR-mutated non-small cell lung cancer (NSCLC) occurs in 5-20% of cases.
- MET amplification is a known mechanism of acquired resistance to EGFR-TKI therapy.
- The impact of MET amplification on tumor and patient phenotype is not well understood.
Purpose of the Study:
- To investigate the in vitro and in vivo effects of MET amplification on the biological properties of EGFR-mutated NSCLC cells.
- To evaluate the clinical significance of MET amplification in EGFR-mutated NSCLC patients progressing on EGFR-TKI therapy.
Main Methods:
- In vitro studies using the HCC827 cell line (EGFR-mutated NSCLC) to assess the impact of MET amplification on proliferation, anchorage-independent growth, anoikis resistance, migration, and epithelial-to-mesenchymal transition.
- In vivo studies to evaluate tumor growth and metastatic spread in a xenograft model.
- Clinical analysis of EGFR-mutated NSCLC patients with MET amplification or high MET overexpression on re-biopsy after EGFR-TKI progression.
Main Results:
- MET amplification significantly enhanced proliferation, anchorage-independent growth, anoikis resistance, migration, and induced epithelial-to-mesenchymal transition in vitro.
- In vivo, MET amplification led to increased tumor growth and metastatic spread.
- MET-TKI treatment reversed the aggressive phenotype induced by MET amplification.
- Patients with MET amplification showed a shorter time to new metastases after EGFR-TKI progression compared to those with high MET overexpression without amplification.
Conclusions:
- MET amplification promotes metastatic spread in EGFR-mutated NSCLC, even with an existing driver mutation.
- These findings highlight the need for therapeutic strategies to prevent or target MET amplification in NSCLC.
- Targeting MET signaling is a promising approach for overcoming acquired resistance to EGFR-TKI therapy.
More Related Videos
09:38Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure
Published on: August 11, 2017
15:05Deciphering the Structural Effects of Activating EGFR Somatic Mutations with Molecular Dynamics Simulation
Published on: May 20, 2020
Related Concept Videos
Mutations
Mutations
Chromosomal Alterations Are Large-Scale Mutations
While point mutations are changes in a single nucleotide in...
Spreading of Chromatin Modifications
Writers
The writer...
Viral Mutations
Mutation, Gene Flow, and Genetic Drift
Increasing Function